

ASX Release

European patent granted for GaRP product

Highlights

- GaRP has been granted a European patent, expanding the intellectual property protection for the product
- The granted patent is being validated in 19 major European countries plus the United Kingdom and provides protection until March 2039, with patent applications on-going in all major jurisdictions.
- The commercial opportunity for non-prescription products for gastrointestinal disorders and IBS is US\$8 billion in the US alone.¹

ADELAIDE, 20 September 2024: Anatara Lifesciences (ASX: ANR or “the Company”), a developer of evidence-based health solutions with a focus on gastrointestinal diseases, is pleased to report the Company has received notification of a decision to grant a European patent from the European Patent Office (EPO) for the title and documents relating to its **Gastrointestinal ReProgramming** product (known as “GaRP”). The decision from the EPO took effect from the publication of the grant in the European Patent Bulletin 24/38 on the 18th September 2024.

Anatara’s Executive Chair Dr. David Brookes commented: *“We are very pleased to see the uniqueness of GaRP being confirmed with this patent grant. The mechanism of action of GaRP is based on ingredients designed to restore and maintain the gastrointestinal tract lining and dynamics, using sophisticated coatings and combinations. This potentially has broad health indications and we look forward to the progress of our current Phase II GaRP-IBS trial in establishing efficacy data. A successful conclusion of the Irritable Bowel Syndrome (IBS) clinical trial is obviously a key consideration for market differentiation and commercialisation.”*

GaRP has the potential to be a disease-modifying treatment that aims to positively impact a substantial proportion of the population that suffer from the debilitating symptoms of digestive disorders, including irritable bowel syndrome (IBS). Due to the mechanism of action, GaRP is expected to be applicable to a wide range of indications in gastrointestinal health beyond IBS.

The lack of efficacious digestive treatments underscores the clear unmet need and the significant market opportunity for Anatara. The commercial opportunity for non-prescription products for gastrointestinal disorders and IBS is US\$8 billion in the USA.²

¹ <https://www.grandviewresearch.com/press-release/global-brain-health-supplements-market>

² <https://www.grandviewresearch.com/press-release/global-brain-health-supplements-market>



About GaRP

Anatara's GaRP product is a multi-component, multi-coated complementary medicine designed to address underlying factors associated with chronic gastrointestinal conditions such as IBS and IBD. GaRP is the working name for the product from the Company's **Gastrointestinal ReProgramming** project that was designed to assist restoration and maintenance of the gastrointestinal tract (GIT) lining as a barrier and assist the homeostasis of the microbiome. The product is made of GRAS (Generally Regarded As Safe) components.

For more information please contact:

Dr. David Brookes
Chair, Anatara Lifesciences Ltd
+61 (0) 411 712 579
dbrookes@anatara.com

Dirk van Dissel
Candour Advisory – Investor Relations
+61 (0) 408 326 367
dirk@candouradvisory.com.au

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based health products where there is significant unmet need. Anatara is focused on building a pipeline of human health products with a particular focus on conditions that involve the complexity of the gastrointestinal tract. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anatara Lifesciences Limited

Registered Office

C/-PERKS Level 8,81 Flinders Street, Adelaide SA 5000

Email info@anatara.com | Website anataralifesciences.com

For personal use only

